The research-based biopharmaceutical company AbbVie (ABBV) is scheduled to report its latest quarterly numbers on Wednesday. In our last technical review back on December 7, we wrote that "The bulls are back in charge with ABBV. Prices are pointed higher. Trade ABBV from the long side risking to $114. The $133 area is our first price target."
Let's visit with charts again.